Sormani MP, Häring DA, Kropshofer H, et al. Blood NfL as a potential endpoint in Phase 2 clinical studies in relapsing-remitting multiple sclerosis. ECTRIMS 2017, 277.
Biomarkers kunnen 'Lewy body'-dementie van Alzheimer onderscheiden
okt 2023 | Dementie